| Metric | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Grant revenue | $7.1M | $0 | — | — |
| Research and development | $8.4M+531.4% | $1.3M-84.3% | $8.5M-9.8% | $9.4M |
| General and administrative | $6.5M+204.8% | $2.1M-71.3% | $7.4M+15.5% | $6.4M |
| Total operating expenses | $15.0M+330.4% | $3.5M | — | — |
| Loss from operations | -$7.8M-124.8% | -$3.5M+85.9% | -$24.7M-54.5% | -$16.0M |
| Other income (expense) | $5.4M+326.9% | -$2.4M | — | — |
| Interest income | $219K+252.6% | $62K-54.7% | $137K+20.3% | $114K |
| Interest expense | $0+100.0% | -$587 | — | — |
| Total other income (expense) | $5.6M+342.4% | -$2.3M | — | — |
| Net income (loss) | -$2.2M+62.6% | -$5.8M+75.9% | -$24.1M-69.9% | -$14.2M |
| Net income (loss) per share of common stock - basic (in dollars per share) | -$0.82+92.7% | -$11.20+9.5% | -$12.38-4026.7% | -$0.30 |
| Weighted average shares outstanding - basic (in shares) | 2.7M+413.6% | 518K | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.